Andrea Vitali Selected Research

taxane

6/2012

An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrea Vitali Research Topics

Disease

2	Infections 09/2022 - 01/2013
1	Breast Neoplasms (Breast Cancer) 05/2023
1	Tissue Adhesions 01/2023
1	COVID-19 09/2022
1	Stroke (Strokes) 05/2021
1	Cognitive Dysfunction 05/2021
1	Lymphedema (Milroy Disease) 01/2021
1	Spinal Cord Injuries (Spinal Cord Injury) 11/2020
1	Neoplasms (Cancer) 06/2012
1	Ovarian Neoplasms (Ovarian Cancer) 06/2012
1	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 03/2012

Drug/Important Bio-Agent (IBA)

1	ethoprop (Mocap)IBA 05/2023
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 01/2023
1	Carboxymethylcellulose Sodium (Polycell)FDA Link 01/2023
1	VaccinesIBA 09/2022
1	SolutionsIBA 11/2020
1	LipopolysaccharidesIBA 01/2013
1	Toll-Like Receptor 4IBA 01/2013
1	Bortezomib (Velcade)FDA Link 06/2012
1	taxaneIBA 06/2012
1	Proteasome InhibitorsIBA 06/2012
1	liposomal doxorubicin (Doxil)FDA Link 06/2012
1	PlatinumIBA 06/2012
1	1-dodecylpyridoxal (PLD)IBA 06/2012

Therapy/Procedure

2	Telerehabilitation 05/2023 - 05/2021
1	Compression Stockings 01/2021
1	Cardiac Resynchronization Therapy 03/2012